From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Pharma manufacturers have complex go-to-market models, consisting of an array of payer and channel contracts, patient support programs, government contracts, and other relationships. All of these involve a myriad of fees, discounts, rebates, and other factors including product returns and inventory adjustments which dramatically impact the gross selling price. Pharma Gross-to-Net (GTN) processes identify the true net-price, forecast future discounts, and develop an optimal pricing strategy.
Being able to accurately calculate and forecast accruals is vital to our financial planning process and ability to meet our financial goals.”
Vice President | Finance
GTN Forecasts | GTN Accruals | GTN Analytics
The graphic shows a breakdown of factors related to pharmaceutical Gross-to-Net (GTN) forecasting.
Challenges Your Team May Face
IntegriChain can help you overcome the traditional data, process, and resource-related challenges associated with gross-to-net and net-pricing visibility for pharma manufacturing companies. We are experts at understanding the dependencies gross-to-net has on channel, patient, and payer data.
Our comprehensive approach to pharmaceutical gross-to-net includes:
Achieving a confident forecast and clear view into a drug’s true net-price can be a major challenge. This can be due to each department running their own gross-to-net spreadsheets and the almost endless array of fees, discounts, chargebacks, credits, and rebates.
The ICyte Platform makes it easier for the gross-to-net (GTN) forecasters to obtain inputs from key stakeholders such as contracts and pricing, channel partners, and patient support. Teams responsible for areas such as pricing, payer deal-making, and co-pay card programs can also model future business strategies in the same platform where overall gross-to-net forecasts are built, leading to a much easier exchange of critical forecast inputs.
Gross-to-Net 2021: An Industry Snapshot Case Study: Making Gross-to-Net a Reality
